Overall, colorectal cancer cells evade EGFR blockade through two main strategies: (a) reactivation of the MAPK-ERK signaling pathway either by mutations in the pathway genes, alterations in alternative tyrosine-kinase receptors, or ligands overexpression (b) lack of binding of cetuximab/panitumumab to the receptor by mutations in the binding epitope located in the extracellular domain of EGFR (Misale et al., 2015; Siravegna et al., 2015). The gene discussed is EGFR; the disease is colorectal cancer.